skip to main content

Spironolactone potassium 5.8 — GPhC CRA MCQ

Instant feedback + full explanation. One question, done properly.

ModerateRenal and Hepatic ImpairmentSpironolactone potassium 5.8GPhC CRA

A woman with CKD taking spironolactone and ramipril has potassium 5.8 mmol/L on repeat testing. What is the most appropriate action?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: C — Withhold and contact the prescriber urgently

This scenario assesses Spironolactone potassium 5.8 in a UK pharmacy practice context. Spironolactone and ACE inhibitors can cause clinically significant hyperkalaemia in CKD. The best answer is Withhold and contact the prescriber urgently because it addresses the principal clinical, legal or safety issue before routine supply. The other options are less appropriate because they either miss the key risk, delay necessary review, or would not meet expected BNF, NICE, MEP, MHRA or GPhC practice standards.

Reference: BNF; NICE CKS